Clinical Trial Applications - Stopped: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 7, showing 10 Applications out of 68 total, starting on record 31, ending on 40

# Protocol No Study Title Investigator(s) & Site(s) Date Stopped

31.

ECCT/22/03/09   GBT 132-Inclacumub PH3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Videlis N Nduba
2. Bernhards Ragama Ogutu
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. KEMRI Siaya Clinical Research Annex (Siaya county)
2. KEMRI/CRDR (Nairobi City county)
3. International Cancer Institute (ICI)-Eldoret (Uasin Gishu county)
4. Strathmore University Medical Centre (Nairobi City county)
 
Not recorded View

32.

ECCT/22/03/01   The \"NOVATION-1\" Trial
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon + SOC vs. Placebo + SOC in Hospitalized Adult Patients with Moderate to Severe COVID-19   
Principal Investigator(s)
1. Dr John Kinuthia
Site(s) in Kenya
1. Center for Research in Therapeutic Sciences(CREATES) (Nairobi City county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. KEMRI Kericho (Kericho county)
4. KEMRI Siaya (Kisumu county)
5. Kenyatta National Hospital (Nairobi City county)
 
Not recorded View

33.

ECCT/22/01/06   AIKILI Technology
    Feasibility and accuracy of nanosensor-based breast cancer diagnosis at the point-of-care-AIKILI technology       
Principal Investigator(s)
1. Laura Kelley Kelley
Site(s) in Kenya
Aga Khan University Hospital, Nairobi.
 
Not recorded View

34.

ECCT/21/12/07   GBT 132- Inclacumab Phase 3
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Videlis N Nduba
3. Fredrick Asirwa Chite
Site(s) in Kenya
1. Strathmore University Medical Centre (Nairobi City county)
2. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
3. KEMRI/CRDR (Nairobi City county)
4. KEMRI Siaya Clinical Research Annex (Siaya county)
 
Not recorded View

35.

ECCT/21/12/04   FAST Study
    Assessments of the EFficacy, the onset-of-Action and the Safety of Tot'héma® in adults with moderate iron deficiency anaemia   
Principal Investigator(s)
1. Dr. Francis Xavier Otieno Odawa
Site(s) in Kenya
1. MOI University Teaching and Referral Hospital (Nandi county)
2. UNIM Research and Training Centre (Kisumu county)
3. Kenyatta National Hospital (Nairobi City county)
 
Not recorded View

36.

ECCT/21/12/02   The WHO ACTION Trial
    ACTION III: A multi-country, multi-centre, three-arm, parallel group, double-blind, placebo-controlled, randomized trial of two doses of antenatal corticosteroids for women with a high probability of birth in the late preterm period in hospitals in low-resource countries to improve newborn outcomes   
Principal Investigator(s)
1. Frederick Namenya Were
2. John Kinuthia
3. Zahida Parveen Qureshi
Site(s) in Kenya
1. Coast General Teaching and Referral Hospital (Mombasa county)
2. Thika Level 5 Hospital (Kiambu county)
3. Nakuru Level 5 Hospital (Nakuru county)
 
Not recorded View

37.

ECCT/21/11/06   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease    
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county)
2. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county)
 
Not recorded View

38.

ECCT/21/10/02   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Janet Oyieko
Site(s) in Kenya
1. KEMRI CCR- Butere County Hospital (Kisumu county)
2. Strathmore University (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI/CRDR Siaya Clinical Research Annex (Siaya county)
5. KEMRI CRDR Clinical Research Clinic Nairobi (Nairobi City county)
6. Gertrude’s Children’s Hospital (Nairobi City county)
 
Not recorded View

39.

ECCT/21/07/06   GBT132_Inclacumab-Ps 3 Trial
    A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises.   
Principal Investigator(s)
1. Fredrick Asirwa Chite
2. Videlis N Nduba
3. Bernhards Ragama Ogutu
Site(s) in Kenya
1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county)
2. KEMRI/CRDR (Nairobi City county)
3. KEMRI Siaya Clinical Research Annex (Siaya county)
4. Strathmore University Medical Centre (Nairobi City county)
 
Not recorded View

40.

ECCT/21/07/01   RESOLVE
    A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell DiseaseA Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Voxelotor for the Treatment of Leg Ulcers in Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Bernhards Ragama Ogutu
2. Jessie Nyokabi Githanga
Site(s) in Kenya
1. Strathmore University Medical Center (Nairobi City county)
2. KEMRI Kondele children\'S Hospital (Kisumu county)
3. Gertrude\'s Children\'s Hospital (Nairobi City county)
 
Not recorded View